Lipid nanoparticles (LNPs) are nanocarriers composed of four lipid components and can be used for gene therapy, protein replacement, and vaccine development. However, LNPs also face several challenges, such as toxicity, immune activation, and low delivery efficiency. To overcome these challenges, artificial intelligence can be used to optimize the design and formulation of LNPs, as well as to predict their properties and performance. Moreover, antibody-targeted conjugation can be used to enhance the specificity and selectivity of LNPs by attaching an antibody that recognizes a specific antigen on the cell surface to LNPs.